β-阻断剂眼药对脉冲率,眼部血流和玻璃眼病进展的影响:一项追溯纵向研究
Naoki Kiyota1, Yukihiro Shiga1, Takahiro Ninomiya1
1Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Advances in therapy
|January 3, 2024
概括
贝塔阻断剂眼滴有效地降低了青光眼患者的脉率 (PR). 像女性性别和较高的d-ROM水平这样的因素预测了更大的PR降低,在特定的亚组中改善胆道血流和更慢的青光眼进展.
科学领域:
- 眼科医生 眼科 眼科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青光眼的管理通常涉及多种药物.
- 贝塔抑制剂通常用于绿眼治疗.
- 了解影响β抑制剂疗效的因素对于患者护理至关重要.
研究的目的:
- 确定与β阻断剂眼滴在改变青光眼患者脉冲率 (PR) 的有效性相关的因素.
- 确定可能从β阻断剂补充疗法中获得额外益处的患者子组.
主要方法:
- 对138名青光眼患者的236只眼睛进行了回顾性研究.
- 收集的数据包括脉冲率 (PR),胆道血流 (平均模糊率 - MBR) 和双色球反应性氧代谢物 (d-ROM).
- 多变量线性混合效应模型和k-means集群被用于分析.
主要成果:
- 贝塔阻断剂眼滴补充剂显著降低了PR (-7.61bpm,P<0.001).
- 女性性别,较高的基线PR,较低的中枢角膜厚度和较高的d-ROM水平与更大的PR降低有关 (P <0.05).
- 在一个特定的患者群体中,胸腔内膜的MBR增加了 (+3.42%) 和青光眼的进展 (MD斜率) 改善了 (+0.64dB/年).
结论:
- 一个小组的玻璃眼病患者经历了PR的降低,胆道血流的增加,并减缓了玻璃眼病的进展与β阻断剂眼滴补充剂.
- 这些发现突出了个性化治疗策略在绿眼管理中的潜力.
相关概念视频
Open Angle Glaucoma: Treatment
453
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
453
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
813
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
813
Glaucoma: Overview
574
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
574
Angle Closure Glaucoma: Treatment
505
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
505
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Adrenergic Antagonists: ɑ and β-Receptor Blockers
453
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
453


